<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04538781</url>
  </required_header>
  <id_info>
    <org_study_id>PTL 0617</org_study_id>
    <nct_id>NCT04538781</nct_id>
  </id_info>
  <brief_title>AMBULATE VASCADE MVP Same Day Discharge Retrospective Registry</brief_title>
  <official_title>AMBULATE VASCADE MVP Same Day Discharge Retrospective Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiva Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardiva Medical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center, retrospective, single arm post market registry to evaluate procedural&#xD;
      outcomes data using the Cardiva VASCADE MVP Venous Vascular Closure System (VVCS) for the&#xD;
      management of the femoral venotomy after catheter-based atrial fibrillation interventions&#xD;
      with or without another arrythmia performed via 6-12F procedural sheaths with single or&#xD;
      multiple access sites per limb for patients who are discharged the same day.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 9, 2020</start_date>
  <completion_date type="Actual">February 8, 2021</completion_date>
  <primary_completion_date type="Actual">January 11, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from next day access site closure-related complications requiring hospital intervention</measure>
    <time_frame>1 day</time_frame>
    <description>Primary Performance Outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>rate of major venous access site closure-related complications</measure>
    <time_frame>≥7 days</time_frame>
    <description>Major Complication rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom from next day procedure-related complications requiring hospital intervention</measure>
    <time_frame>1 day</time_frame>
    <description>Secondary Performance Outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from access site closure-related complications requiring hospital intervention through standard of care follow up contact</measure>
    <time_frame>≥7 days</time_frame>
    <description>Secondary Performance Outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>minor venous access site closure-related complications</measure>
    <time_frame>≥7 days</time_frame>
    <description>Minor Complication rate</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">497</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Same Day Discharge</arm_group_label>
    <description>Patients undergoing a-fib ablation procedures who were closed with VASCADE MVP and were discharged the same day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VASCADE MVP VVCS</intervention_name>
    <description>The VASCADE MVP Venous Vascular Closure System (VVCS) is indicated for the percutaneous closure of femoral venous access sites while reducing time to ambulation, total post-procedure time, time to hemostasis, and time to discharge eligibility in patients who have undergone catheter-based procedures utilizing 6 - 12F inner diameter (maximum 15F OD) procedural sheaths, with single or multiple access sites in one or both limbs.</description>
    <arm_group_label>Same Day Discharge</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All subjects 1) treated for A-Fib with or without another arrythmia via catheter ablation&#xD;
        2) who received VASCADE MVP with no other vascular closure device and 3) were discharged&#xD;
        the same calendar day during the retrospective date range.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ≥18 years of age;&#xD;
&#xD;
          2. Underwent catheter-based ablation for atrial fibrillation with or without another&#xD;
             arrythmia.&#xD;
&#xD;
          3. VASCADE MVP was the only closure device utilized.&#xD;
&#xD;
          4. Were discharged the same calendar day as the index procedure.&#xD;
&#xD;
          5. Completed a SOC follow-up &gt; 7 days post-procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Any additional procedure(s) involving femoral arterial or venous access in either limb&#xD;
        within the SOC follow up period as defined by each site (minimum 7 days post-procedure)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Coastal Cardiology</name>
      <address>
        <city>San Luis Obispo</city>
        <state>California</state>
        <zip>93401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Washington</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahey Clinic</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 31, 2020</study_first_submitted>
  <study_first_submitted_qc>August 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2020</study_first_posted>
  <last_update_submitted>February 26, 2021</last_update_submitted>
  <last_update_submitted_qc>February 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

